EPO pharma case law trends 2025: Clinical inventions By Dr Rose Hughes at Monday, November 24, 2025 epo EPO Boards of Appeal PatKat pharma ip Rose Hughes Second medical use +
EPO pharma case law trends 2025: Antibodies and biologics By Dr Rose Hughes at Monday, November 17, 2025 antibodies antibody inventions biologics epo EPO Boards of Appeal PatKat Rose Hughes +
Never Too Late: If you missed the IPKat last week! By Asude Sena Moya at Tuesday, March 25, 2025 #NeverTooLate AI Artificial Intelligence Asude Sena Moya authorship cell therapy colour marks copyright designs EPO Boards of Appeal inventive step ip strategy originality plant varieties trade marks +
Excluding a technical feature is not inventive without evidence of a technical effect (T 1865/22) By Dr Rose Hughes at Friday, March 21, 2025 epo EPO Boards of Appeal G1/21 inventive step PatKat Rose Hughes +
Functional claims for pharmaceutical formulations: Validity versus enforcement (T 2130/22) By Dr Rose Hughes at Friday, January 24, 2025 epo EPO Boards of Appeal formulation. patents G2/21 inventive step ip strategy patents PatKat pharma ip plausibility Rose Hughes +
The morality (and patentability) of inventions derived by immoral means (T 2510/18) By Dr Rose Hughes at Thursday, October 31, 2024 Article 53(a) EPC epo EPO Boards of Appeal G 1/23 patents PatKat prior use Rose Hughes +
Stretching the cheese: Contradictory evidence for a purported technical effect relied on for inventive step (T 0629/22) By Dr Rose Hughes at Monday, May 13, 2024 epo EPO Boards of Appeal G 2/21 G2/21 inventive step patents PatKat plausibility Rose Hughes +